Syros Pharmaceuticals Stock - business model in focus after Nasdaq delisting

Edited by ad hoc news Long-Term & Business-Model Desk. Verified prior to publication on 06/20/2026, 17:14 CET. Details in the imprint.

Syros Pharmaceuticals (US8719201096) has become a micro-cap biotech name after its shares slid to $0.0001 and trading effectively ceased on Nasdaq, according to the latest consolidated quote data from MarketBeat. With no fresh corporate news, the focus now shifts to the company’s underlying business model and gene-control pipeline.

Long-term strategy under pressure

Syros Pharmaceuticals has positioned itself as a clinical-stage biopharmaceutical company using gene control to develop targeted therapies for cancer and other serious diseases. Its strategy centers on identifying regulators of gene expression and drugging them with small molecules.

The company historically highlighted multiple clinical programs, including in hematological malignancies, and collaborations intended to help fund research. According to its corporate overview, Syros aimed to build a diversified pipeline rather than rely on a single asset.

Funding needs and historical losses

Like many early-stage biotech companies, Syros has reported persistent net losses while funding research and development. MarketBeat data show a trailing twelve-month net loss of about $164.6 million and negative earnings per share of $3.03.

For its most recently reported quarter, the company posted a loss of $0.68 per share, slightly better than the consensus estimate for a $0.76 loss. That positive surprise did not change the broader picture of a business still dependent on external capital rather than operating cash flow.

How the business model works

Syros Pharmaceuticals describes itself as a pioneer in gene control medicines, looking for regulatory elements in DNA that govern how and when genes are expressed. The company then tries to design drugs that can modulate these switches and correct disease-driving gene expression programs.

This model is capital-intensive, with long development cycles and binary clinical milestones. Management has historically combined in-house programs with potential partnering deals to share costs and access upfront payments and milestones.

Where the stock trades today

The shares of Syros Pharmaceuticals (US8719201096) last traded on Nasdaq at $0.0001, based on consolidated quote data as of 06/18/2026, 13:44 ET.

This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.